China Jo-Jo Drugstores Reports Fiscal Year 2022 Financial Results
HANGZHOU, China, July 28, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2022.
Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased with our fiscal year 2022 financial results, which reflect our continued growth momentum that we have achieved overall improvement across all key financial metrics. Compared with fiscal year 2021, our total revenue and gross profit increased by 23.5% and 24.9%, respectively, while our net loss narrowed down by 61.8%. Our solid financial performance demonstrates the resilience of our business and the reliability of our current business strategies in the current challenging market amid COVID-19 pandemic. Through leveraging the advantage of our stable supplier network, extensive distribution channels, and deep customer connections, we have proven our capability to execute our multifaceted growth plan and scale our business. Our dedicated team continues to provide high-quality services to customers, which has improved our brand awareness, strengthened customer relationships and distinguished us from peers in the market."
Mr. Liu continued, "The project of 'Healthy China 2030' advances the healthcare sector reforms and greatly enhances overall medical service quality and efficiency in China. We remain confident in the business we've built and our ability to capture the significant opportunity going forward brought by the project of 'Healthy China 2030'. We will continue to focus on executing our growth strategy and drive initiatives to deliver sustainable development. To realize the potential of our business model, we have enhanced various information and data systems, continued to develop the management system for patients with chronic diseases, upgraded our 'Medical + Medicine' business model, introduced digital services, developed 24-hour service stores, launched a new Office Automation system, and accelerated comprehensive budget management. We look forward to bringing our excellent services and products to more customers and continuing to add value to our existing customers. We will keep our efforts in investing in our team and business, expanding our distribution network, growing our customer base and building continued momentum toward our growth objectives. We believe that we are well-positioned to deliver profitable growth over the long-term and generate long-term shareholder value."
Fiscal Year 2022 Financial Highlights
For the Year Ended March 31, | ||||||
($ millions, except per share data) | 2022 | 2021 | % Change | |||
Revenue | 164.39 | 133.13 | 23.5 % | |||
Retail drugstores | 84.23 | 76.10 | 10.7 % | |||
Online pharmacy | 30.22 | 22.48 | 34.4 % | |||
Wholesale | 49.94 | 34.55 | 44.6 % | |||
Gross profit | 36.52 | 29.24 | 24.9 % | |||
Gross margin | 22.2 % | 22.0 % | 0.2 pp* | |||
Loss from operations | (2.69) | (8.84) | 69.5 % | |||
Net loss | (3.20) | (8.38) | 61.8 % | |||
Loss per share | (0.92) | (2.39) | 61.5 % | |||
*Notes: pp represents percentage points | ||||||
- Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year.
- Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year.
- Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year.
- Net loss was $3.20 million, or $0.92 per basic and diluted share, for the fiscal year ended March 31, 2022, compared to net loss of $8.38 million, or $2.39 per basic and diluted share, for the same period of last year.
Fiscal Year 2022 Financial Results
Revenue
Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.
For the Year Ended March 31, | ||||||||||||
2022 | 2021 | |||||||||||
($ millions) | Revenue | Cost of Goods | Gross Margin | Revenue | Cost of Goods | Gross Margin | ||||||
Retail drugstores | 84.23 | 57.29 | 32.0 % | 76.10 | 53.09 | 30.2 % | ||||||
Online pharmacy | 30.22 | 26.62 | 11.9 % | 22.48 | 20.15 | 10.4 % | ||||||
Wholesale | 49.94 | 43.96 | 12.0 % | 34.55 | 30.65 | 11.3 % | ||||||
Total | 164.39 | 127.87 | 22.2 % | 133.13 | 103.89 | 22.0 % | ||||||
Revenue from the retail drugstores business increased by $8.13 million, or 10.7%, to $84.23 million for the fiscal year ended March 31, 2022 from $76.10 million for the same period of last year. After excluding the impact of exchange rate fluctuation, the actual retail drugstores sales increased by 5.2%. The actual increase in retail drugstore sales was primarily due to continuous adjustments of merchandises, suitable to the market and improved store employee incentive plan, and contribution from the new store sales.
Revenue from the online pharmacy business increased by $7.74 million, or 34.4%, to $30.22 million for the fiscal year ended March 31, 2022 from $22.48 million for the same period of last year. The increase was primarily caused by sales to commercial insurance customers via the Company's official website and an increase in sales of prescription drugs via e-commerce platforms such as Tmall. The sales via the Company's official website were primarily made by certain pharmacy benefit management providers and insurance companies. For example, the Company has signed a service contract with Yingda Taihe Life Insurance Co. Ltd. ("Yingda"), a national insurance company. Certain companies bought private health insurances from Yingda for their employees. By linking the Company's online pharmacy platform with Yingda and training Yingda's employees, they are able to buy health products on the Company's online stores. The sales from these customers contributed significantly to the Company's official website sales.
Prescription drugs used to be prohibited from online sales due to safety concern. After the nation has lifted the ban order, online prescription drug sales become popular. As a result, the sale of prescription drugs was $10.33 million for the fiscal year ended March 31, 2022 as compared to $8.24 million for the same period of last year.
Revenue from the wholesale business increased by $15.39 million, or 44.6%, to $49.94 million for the fiscal year ended March 31, 2022, from $34.55 million for the same period of last year. In order to obtain rebates from its major suppliers, the Company is required to make more purchase from the suppliers. To quickly resell these products, the Company chose to lower its sales price to local vendors, which in turn helped increase the sales significantly.
Gross profit and gross margin
Total cost of goods sold increased by $23.98 million, or 23.1%, to $127.87 million for the fiscal year ended March 31, 2022, from $103.89 million for the same period of last year. Gross profit increased by $7.28 million, or 24.9%, to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Overall gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022, from 22.0% for the same period of last year, due to higher retail drugstores profit margins.
Gross margins for retail drugstores, online pharmacy and wholesale were 32.0%, 11.9%, and 12.0%, respectively, for the fiscal year ended March 31, 2022, compared to gross margins for retail drugstores, online pharmacy and wholesale of 30.2%, 10.4%, and 11.3%, respectively, for the same period of last year.
Loss from operations
Selling and marketing expenses increased by $3.93 million, or 14.6%, to $30.88 million for the fiscal year ended March 31, 2022 from $26.95 million for the same period of last year. The increase in selling and marketing expenses was primarily due to increase in rent and the sales and marketing expenses.
General and administrative expenses decreased by $2.71 million, or 24.9%, to $8.19 million for the fiscal year ended March 31, 2022 from $10.90 million for the same period of last year. The decrease in general and administrative expenses was primarily due to the decrease in stock-based compensation, offset by the increase in bad debt expense. In December 2020, the Company issued a total of 3,790,000 shares of common stock and recorded stock-based compensation of approximately $3.94 million. In the year ended March 31, 2021, the Company recorded the reduction in the allowance for bad debts of $0.17 million as compared to the increase in the allowance for bad debts of $1.0 million in fiscal year 2022.
Loss from operations was $2.69 million for the fiscal year ended March 31, 2022, compared to $8.84 million for the same period of last year. Operating margin was (1.6) % and (6.6)% for the fiscal year ended March 31, 2022 and 2021, respectively.
Net loss
Net loss was $3.20 million, or $0.92 per basic and diluted share for the fiscal year ended March 31, 2022, compared to net loss of $8.38 million, or $2.39 per basic and diluted share for the same period of last year.
Financial Condition
As of March 31, 2022, the Company had cash of $18.46 million, compared to $22.05 million as of March 31, 2021. Net cash used in operating activities was $5.39 million for the fiscal year ended March 31, 2022, compared to $0.06 million for the same period of last year. The change is primarily attributable to a decrease in cash provided by accounts payable of $9,938,165, a decrease in cash provided by stock compensation of $3,941,600, a decrease in cash provided by other receivables of $2,396,659 offset by an increase of $5,138,115 in inventories and biological assets, an increase in cash provided by net loss of $5,177,212. Net cash used in investing activities was $0.31 million for the fiscal year ended March 31, 2022, compared to $2.00 million for the same period of last year. The change is primarily attributable to an increase in cash provided by investment in a joint venture of $1,470,119 and an increase of $170,445 in additions to leasehold improvements. Net cash provided by financing activities was $4.84 million for the fiscal year ended March 31, 2022, compared to $3.08 million for the same period of last year. The change is primarily due to repayment of notes payable and proceeds from equity and debt financing.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Chief Financial Officer
+86-571-88077108
[email protected]
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-917-609-0333
[email protected]
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | ||||||||
March 31, | March 31, | |||||||
2022 | 2021 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 18,458,575 | $ | 22,045,628 | ||||
Restricted cash | 16,881,002 | 12,627,016 | ||||||
Financial assets available for sale | 94,648 | 91,472 | ||||||
Notes receivable | - | 39,392 | ||||||
Trade accounts receivable | 16,736,495 | 13,423,728 | ||||||
Inventories | 16,020,140 | 16,972,965 | ||||||
Other receivables, net | 5,764,660 | 5,051,960 | ||||||
Advances to suppliers | 571,577 | 421,963 | ||||||
Other current assets | 924,797 | 1,560,119 | ||||||
Total current assets | 75,451,894 | 72,234,243 | ||||||
PROPERTY AND EQUIPMENT, net | 5,922,179 | 6,549,035 | ||||||
OTHER ASSETS | ||||||||
Long-term investment | 4,416,891 | 3,981,986 | ||||||
Farmland assets | 722,283 | 835,427 | ||||||
Long term deposits | 1,761,945 | 1,546,764 | ||||||
Other noncurrent assets | 822,950 | 856,391 | ||||||
Operating lease right-of-use assets | 13,738,081 | 16,778,729 | ||||||
Intangible assets, net | 3,547,986 | 3,528,056 | ||||||
Total other assets | 25,010,136 | 27,527,353 | ||||||
Total assets | $ | 106,384,209 | $ | 106,310,631 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY(DEFICIT) | ||||||||
CURRENT LIABILITIES | ||||||||
Short-term bank loan | - | 762,270 | ||||||
Accounts payable, trade | 27,331,381 | 29,895,830 | ||||||
Notes payable | 34,189,022 | 25,663,633 | ||||||
Other payables | 2,268,967 | 2,940,000 | ||||||
Other payables - related parties | 1,561,244 | 445,305 | ||||||
Customer deposits | 1,873,062 | 1,146,247 | ||||||
Taxes payable | 1,381,108 | 197,733 | ||||||
Accrued liabilities | 556,037 | 501,111 | ||||||
Long-term loan payable-current portion | 1,957,956 | 2,557,634 | ||||||
Current portion of operating lease liabilities | 3,329,619 | 788,171 | ||||||
Total current liabilities | 74,448,396 | 64,897,934 | ||||||
Long-term loan payable | - | 1,892,269 | ||||||
Long term operating lease liabilities | 9,197,027 | 15,118,083 | ||||||
Employee Deposits | - | - | ||||||
Purchase option and warrants liability | - | - | ||||||
Total liabilities | 83,645,423 | 81,908,286 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
STOCKHOLDERS' EQUITY(DEFICIT) | ||||||||
Common stock; $0.001 par value; 250,000,000 shares authorized; 3,479,316 and 3,479,316 shares issued and outstanding as of March 31, 2022 and March 31, 2021 | 41,752 | 41,752 | ||||||
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2022 and March 31, 2021 | - | - | ||||||
Additional paid-in capital | 66,516,033 | 66,516,033 | ||||||
Statutory reserves | 1,309,109 | 1,309,109 | ||||||
Accumulated deficit | (48,134,493) | (44,942,374) | ||||||
Accumulated other comprehensive income | 4,352,992 | 2,818,185 | ||||||
Total stockholders' equity | 24,085,393 | 25,742,705 | ||||||
Noncontrolling interests | (1,346,607) | (1,340,360) | ||||||
Total equity | 22,738,786 | 24,402,345 | ||||||
Total liabilities and stockholders' equity | $ | 106,384,209 | $ | 106,310,631 | ||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
For the years ended March 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
REVENUES, NET | $ | 164,392,555 | $ | 133,134,633 | $ | 117,327,689 | ||||||
COST OF GOODS SOLD | 127,873,515 | 103,890,824 | 91,801,259 | |||||||||
GROSS PROFIT | 36,519,040 | 29,243,809 | 25,526,430 | |||||||||
SELLING EXPENSES | 30,876,959 | 26,954,914 | 23,793,603 | |||||||||
GENERAL AND ADMINISTRATIVE EXPENSES | 8,187,176 | 10,897,629 | 8,108,377 | |||||||||
IMPAIRMENT OF LONG-LIVED ASSETS | 148,795 | 228,506 | 628,192 | |||||||||
TOTAL OPERATING EXPENSES | 39,212,930 | 38,081,049 | 32,530,172 | |||||||||
LOSS FROM OPERATIONS | (2,693,890) | (8,837,240) | (7,003,742) | |||||||||
OTHER EXPENSE: | ||||||||||||
INTEREST INCOME | 401,921 | 707,878 | 1,063,747 | |||||||||
INTEREST EXPENSE | (262,218) | (455,187) | (698,518) | |||||||||
OTHER | 455,547 | 176,519 | (204,064) | |||||||||
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY | - | 64,090 | 401,158 | |||||||||
LOSS BEFORE INCOME TAXES | (2,098,640) | (8,343,940) | (6,441,419) | |||||||||
PROVISION FOR INCOME TAXES | 1,099,726 | 31,638 | 16,258 | |||||||||
NET LOSS | (3,198,366) | (8,375,578) | (6,457,677) | |||||||||
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | (6,247) | (255,716) | (644,308) | |||||||||
NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC. | (3,192,119) | (8,119,862) | (5,813,369) | |||||||||
OTHER COMPREHENSIVE LOSS | ||||||||||||
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | 1,534,807 | 1,377,761 | (1,068,540) | |||||||||
COMPREHENSIVE LOSS | (1,663,559) | (6,997,817) | (7,526,217) | |||||||||
WEIGHTED AVERAGE NUMBER OF SHARES: | ||||||||||||
Basic | 3,479,316 | 3,398,397 | 2,734,714 | |||||||||
Diluted | 3,479,316 | 3,398,397 | 2,734,714 | |||||||||
LOSS PER SHARES: | ||||||||||||
Basic | $ | (0.92) | $ | (2.39) | $ | (2.16) | ||||||
Diluted | $ | (0.92) | $ | (2.39) | $ | (2.16) | ||||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
For the years ended March 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||
Net income | $ | (3,198,366) | $ | (8,375,578) | $ | (6,457,677) | ||||||
Adjustments to reconcile net income to net cash used in operating activities: | ||||||||||||
Bad debt direct write-off and provision | 939,720 | (706,862) | 446,354 | |||||||||
Depreciation and amortization | 1,256,491 | 1,750,890 | 2,082,817 | |||||||||
Impairment of long lived assets | 148,795 | 228,506 | 628,192 | |||||||||
Stock based compensation | - | 3,941,600 | 34,560 | |||||||||
Change in fair value of purchase option derivative liability | - | (64,090) | (401,158) | |||||||||
Change in operating assets: | ||||||||||||
Accounts receivable, trade | (2,657,283) | (3,307,946) | (1,567,774) | |||||||||
Notes receivable | 40,260 | 21,539 | 112,803 | |||||||||
Inventories and biological assets | 1,523,098 | (3,615,017) | 979,935 | |||||||||
Other receivables | (1,927,692) | 468,967 | (1,010,722) | |||||||||
Advances to suppliers | (171,783) | 1,893,857 | 148,638 | |||||||||
Long term deposit | (159,508) | 26,910 | 596,209 | |||||||||
Other current assets | 376,134 | 1,004,448 | (1,278,833) | |||||||||
Other noncurrent assets | 62,394 | 38,142 | 87,065 | |||||||||
Change in operating liabilities: | ||||||||||||
Accounts payable, trade | (3,558,050) | 6,380,115 | (317,755) | |||||||||
Other payables and accrued liabilities | 99,132 | (183,111) | (967,751) | |||||||||
Customer deposits | 678,601 | 368,690 | (22,963) | |||||||||
Taxes payable | 1,162,084 | 66,648 | 115 | |||||||||
Net cash used in operating activities | (5,385,972) | (62,292) | (6,907,945) | |||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||
Disposal of financial assets available for sale | - | 75,973 | 14,356 | |||||||||
Purchase of financial assets available for sale | - | - | - | |||||||||
Acquisition of equipment and building | (89,960) | (126,766) | (656,297) | |||||||||
Investment in a joint venture | - | (1,470,119) | (2,567,083) | |||||||||
Purchases of intangible assets | (7,012) | (97,802) | (871,145) | |||||||||
Additions to leasehold improvements | (209,166) | (379,611) | (756,444) | |||||||||
Net cash used in investing activities | (306,138) | (1,998,325) | (4,836,613) | |||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||
Proceeds from short-term bank loan | - | 738,315 | 1,435,620 | |||||||||
Repayment of short-term bank loan | (779,059) | (1,476,630) | - | |||||||||
Proceeds from third parties loan | - | - | 7,178,100 | |||||||||
Repayment of third parties loan | (2,613,965) | (2,395,629) | (658,645) | |||||||||
Proceeds from notes payable | 65,370,181 | 48,292,231 | 48,974,772 | |||||||||
Repayment of notes payable | (57,829,269) | (51,295,776) | (46,896,917) | |||||||||
Increase in financial liability | - | (73,832) | (7,178) | |||||||||
Exercise of warrants | - | 77,500 | - | |||||||||
Proceeds from sale of stock and warrants | - | 9,287,100 | 9,273,077 | |||||||||
Repayment of other payable-related parties | 689,010 | (73,426) | (285,123) | |||||||||
Net cash provided by financing activities | 4,836,898 | 3,079,853 | 19,013,706 | |||||||||
EFFECT OF EXCHANGE RATE ON CASH | 1,522,146 | 2,670,802 | (1,031,744) | |||||||||
INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 666,933 | 3,690,038 | 6,237,404 | |||||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | 34,672,644 | 30,982,606 | 24,745,202 | |||||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | $ | 35,339,577 | $ | 34,672,644 | $ | 30,982,606 | ||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||||||
Cash paid for income taxes | $ | 3,955 | $ | 37,738 | $ | 17,198 | ||||||
Cash paid for interest | 262,218 | 455,187 | 108,098 | |||||||||
View original content:https://www.prnewswire.com/news-releases/china-jo-jo-drugstores-reports-fiscal-year-2022-financial-results-301595017.html
SOURCE China Jo-Jo Drugstores, Inc.